ADMA Biologics (Q1 2026, period ending March 31, 2026) presents a materially positive liquidation posture relative to prior periods, though the asset recovery math still warrants scrutiny given the liability stack that expanded significantly during the quarter. Under liquidation haircuts, recoverable asset value is approximately: cash $138M (100%), AR $122-129M (90-95% on $135.9M), inventory $133M (60% on $222M), PP&E $33-46M (50-70% on $65M net), intangibles and goodwill $0 (zero recovery on $4.2M combined), deferred tax assets $0 (zero recovery on $70M). Total haircutted assets approximate $426-446M. Against total liabilities of $274.9M at face value — including $196.9M in long-term debt (JPM Credit Facilities), $73.5M current liabilities, and $7.5M operating lease obligations — residual equity recovery is roughly $151-171M, a positive outcome. This is a meaningful improvement versus the prior 10-K (December 31, 2025) baseline where working capital was $397M versus the current $437.6M. The most significant change since the prior filing is the $125M draw on the JPM Revolving Facility in March 2026 to fund an accelerated share repurchase (ASR Agreement with JPMorgan), which simultaneously increased long-term debt by $125M and reduced equity via TreasuryStockValue increasing to $143.2M (from an implied lower balance at year-end 2025). The debt-funded buyback shifts the liquidation calculus: cash increased $50.5M net in Q1 2026, but $130.2M was consumed by share repurchases and $125M was drawn on the revolver — indicating the ASR is the dominant cash flow driver, not operations alone. Operationally, Q1 2026 OCF was $58.2M versus negative $19.7M in Q1 2025, driven by AR collections ($22.6M source) and net income of $45.3M. Inventory grew $15.6M in Q1 2026, a continued use of cash, consistent with the 7-12 month production cycle. The JPM Credit Agreement (maturity August 2028) imposes a 2.50x total leverage covenant; at $196.9M outstanding against strong operating income, covenant headroom appears adequate. All obligations are secured by a first-priority lien on substantially all assets including IP. The filing discloses deferred tax assets of $70M, which carry zero recovery value under liquidation. The accumulated deficit stands at -$116.3M despite recent profitability. The MFFAIS CLV of -$135M reflects the full haircut on DTAs and inventory, partially offset by liquid assets; the OLV of $222.6M better reflects the going-concern inventory value. Filing discusses Medicaid rebate accrual estimation risk and voluntary product withdrawal exposure in MD&A but does not separately XBRL-tag these contingent liability amounts.
▼ Community Notes